The next phase of growth is shifting from science to scale — infrastructure is required to produce alternative proteins with precision and consistency required of these systems.

Add Yahoo as a preferred source to see more of our stories on Google. With complex biologics such as monoclonal antibodies (mAb), antibody-drug conjugates (ADCs) and cell and gene therapies (CGTs) ...

Mass production of recombinant proteins using yeast cell "factories" needs methanol, a compound that requires safe handling, carries the risk of catching fire, and sometimes produces harmful ...

Industrial yeasts are a powerhouse of protein production, used to manufacture vaccines, biopharmaceuticals, and other useful compounds. In a new study, MIT chemical engineers have harnessed artificial ...

Proteins are among the most important molecular building blocks of life. They themselves are built from amino acids linked together based on the information in our genetic material. In this process, ...

With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach to protein production as a potential salve. Now, after several years spent ...

The demand for complex therapeutic proteins, is rapidly accelerating, with the bispecific market alone projected to grow to $50B by 2030. While these atypical molecules offer transformative clinical ...

Controlling ribosomal RNA could help researchers target diseases driven by too little or too much protein production.

As protein demand surges, dairy processors are using CIP optimisation, membrane efficiency and AI tools to increase whey ...

With complex biologics such as monoclonal antibodies (mAb), antibody-drug conjugates (ADCs) and cell and gene therapies (CGTs) attracting the attention of global big pharma companies, the scope of ...